What is Pentadecapeptide researched for?

Pentadecapeptide is generally used here as another name for BPC-157, a synthetic 15-amino-acid peptide. The source links it to research on tissue healing, gut health, and injury recovery, but the support described is mainly animal and laboratory evidence rather than completed human clinical proof.

How might Pentadecapeptide work?

The proposed biology is still uncertain. Source evidence points to animal findings involving new blood-vessel formation, VEGFR2-related signaling, nitric oxide pathways, and rodent neurotransmitter systems. A confirmed human receptor target or settled mechanism was not established in the supplied evidence.

Is Pentadecapeptide FDA approved?

No. The source lists Pentadecapeptide as not FDA approved and describes the development status as preclinical, with additional FDA Category 2 reclassification context pending formal regulatory action.

What side effects are reported?

The source reports nausea, dizziness, possible histamine release, and a caution note for people with MCAS or histamine sensitivity. It also says the compound is generally well tolerated, but these statements should be reviewed cautiously because the evidence base is not established in completed human trials.

What dose information is available?

The source says community data are limited. It separately lists a research-style subcutaneous protocol of 250-500 mcg twice daily for 4-12 weeks, but labels the evidence as preclinical rather than a validated human dosing standard.

Healing Preclinical - animal studies only

Pentadecapeptide

Also known as: BPC-157 Full Sequence, Stable Gastric Pentadecapeptide

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

BPC-157-associated peptide in preclinical healing research

Status

Preclinical

Evidence level: animal studies

Typical dose

Limited community data available

Subcutaneous injection

Researched for

Tissue healing, gut health, injury recovery

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Pentadecapeptide is presented as BPC-157, a synthetic 15-amino-acid .
The listed sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
The source frames the evidence as and largely animal-based.
It is not FDA approved in the supplied evidence.
Research interest is listed for tissue healing, gut health, and injury recovery.
Community dosing information is limited, while the source separately reports preclinical research-style dosing.

How it's thought to work

Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes findings suggesting effects on , -associated pathways, signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.

What the research shows

Where the research stands

The supplied source describes a sizeable literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source. Not FDA approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community-reported information is sparse and should be treated as non-validated background rather than evidence of an established human regimen.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

250-500 mcg twice daily

Preclinical research dosing from animal or in-vitro studies

Animal study doses may not translate directly to humans.

Duration: 4-12 weeks typical
Administration: Subcutaneous injection
Frequency: Twice daily

Timing & administration

Best time to take

Morning and evening; sometimes aligned with injury-related activity timing

1-2 times daily, consistent timing

Food recommendation

With or without food

Why this timing?

The source frames split timing as a way to keep exposure more consistent, with possible scheduling around activity in injury-related contexts. This timing rationale is not presented as clinically validated.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Nausea
Dizziness
Possible histamine release

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Pentadecapeptide

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Pentadecapeptide

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions